Pharmacy Joe

DECEMBER 29, 2024

In this episode, Ill discuss recommendations on the dose of cefazolin for a CNS infection. Episode 987: What dose of cefazolin is recommended for a CNS infection? Subscribe on iTunes , Android , or Stitcher When a CNS infection such as meningitis, ventriculitis, or a brain abscess is due to methicillin susceptible staph aureus, an antistaphylococcal penicillin such as nafcillin has been considered the first-line therapy.

Hospitals 52

Hospitals Inpatient 52

Drug Patent Watch

DECEMBER 29, 2024

FENTORA (fentanyl citrate) Cephalon Patent: 8,119,158 Expiration: Dec 30, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.

52

52

Pharmaceutical Technology

DECEMBER 29, 2024

Nelistotug is under clinical development by GSK and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.

40

40

STAT

DECEMBER 29, 2024

Former President Jimmy Carter’s oft-stated desire was to see the last Guinea worm die before he did. Though America’s 39 th president, who died Sunday at age 100, did not quite achieve that dream, he left a huge legacy in the field of global health. The causes he espoused are diseases whose names most of us barely know. Onchocerciasis, or river blindness.

364

364

Speaker: Jennifer Hill

Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.

Pharmaceutical Technology

DECEMBER 29, 2024

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Head And Neck Cancer.

40

40

Pharmaceutical Technology

DECEMBER 29, 2024

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

40

40

Pharmaceutical Technology

DECEMBER 29, 2024

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).

40

40

Pharmaceutical Technology

DECEMBER 29, 2024

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma.

40

40

Pharmaceutical Technology

DECEMBER 29, 2024

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Lupus Nephritis.

40

40

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

Pharmaceutical Technology

DECEMBER 29, 2024

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Follicular Lymphoma.

40

40

Pharmaceutical Technology

DECEMBER 29, 2024

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

40

40

Pharmaceutical Technology

DECEMBER 29, 2024

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy.

40

40

Pharmaceutical Technology

DECEMBER 29, 2024

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL).

40

40

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

Pharmaceutical Technology

DECEMBER 29, 2024

Nelistotug is under clinical development by GSK and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.

40

40

Pharmaceutical Technology

DECEMBER 29, 2024

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Head And Neck Cancer.

40

40

Pharmaceutical Technology

DECEMBER 29, 2024

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

40

40

Pharmaceutical Technology

DECEMBER 29, 2024

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).

40

40

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

Pharmaceutical Technology

DECEMBER 29, 2024

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma.

40

40

Pharmaceutical Technology

DECEMBER 29, 2024

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Lupus Nephritis.

40

40

Pharmaceutical Technology

DECEMBER 29, 2024

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Follicular Lymphoma.

40

40

Pharmaceutical Technology

DECEMBER 29, 2024

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

40

40

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

Pharmaceutical Technology

DECEMBER 29, 2024

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy.

40

40

Pharmaceutical Technology

DECEMBER 29, 2024

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL).

40

40